Cargando…
CGRP Receptor Antagonism in COVID-19: Potential Cardiopulmonary Adverse Effects
Recently, the US FDA has authorized a drug repurposing trial with calcitonin gene-related peptide (CGRP) receptor antagonists to reduce lung inflammation in coronavirus 2019 (COVID-19). However, the well-established cardiopulmonary protective effects of CGRP raise concerns about the safety of antago...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580524/ https://www.ncbi.nlm.nih.gov/pubmed/33129692 http://dx.doi.org/10.1016/j.molmed.2020.10.005 |